26 reports of this reaction
1.7% of all CETYLPYRIDINIUM CHLORIDE reports
#11 most reported adverse reaction
ASTHENIA is the #11 most commonly reported adverse reaction for CETYLPYRIDINIUM CHLORIDE, manufactured by RB Health (US) LLC. There are 26 FDA adverse event reports linking CETYLPYRIDINIUM CHLORIDE to ASTHENIA. This represents approximately 1.7% of all 1,541 adverse event reports for this drug.
Patients taking CETYLPYRIDINIUM CHLORIDE who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for CETYLPYRIDINIUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for CETYLPYRIDINIUM CHLORIDE:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 26 FDA reports for CETYLPYRIDINIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 1.7% of all adverse event reports for CETYLPYRIDINIUM CHLORIDE, making it a notable side effect.
If you experience asthenia while taking CETYLPYRIDINIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.